Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 11/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.40 |
| ▸ | SMO | Q99835 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477152 | 0.89 | HSP90AA1 (0.39) | HSP90AA1HRH1HKDC1MITF | |
| SCHEMBL18477166 | 0.87 | HSP90AA1 (0.38) | HSP90AA1HKDC1 | |
| SCHEMBL18477147 | 0.87 | MEN1 (0.38) | HSP90AA1SMOFNTAFNTBHKDC1 | |
| SCHEMBL18477157 | 0.86 | HSP90AA1 (0.37) | HSP90AA1HRH1HKDC1MITF | |
| SCHEMBL18477165 | 0.86 | LMNA (0.37) | HSP90AA1 | |
| SCHEMBL18479516 | 0.86 | KDM4E (0.47) | — | |
| SCHEMBL18477144 | 0.85 | HSP90AA1 (0.38) | HSP90AA1HKDC1MITF | |
| SCHEMBL18477155 | 0.85 | ALDH1A1 (0.41) | HSP90AA1 | |
| SCHEMBL18477158 | 0.84 | HSP90AA1 (0.45) | HSP90AA1HRH1HKDC1 | |
| SCHEMBL18477866 | 0.84 | MEN1 (0.40) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | NANTBIO, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| WO-2017024315-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | TPMT, MKI67, TST | PTAFR 1946/4885HSP90AA1 158/4885SMO 480/4885 |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | TPMT, MKI67, TST | PTAFR 1946/4885HSP90AA1 158/4885SMO 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.